Study of the efficiency of a novel desensitization protocol based on platelet infusion for decreasing anti-HLA antibody titer and increasing transplant ability
Not Applicable
Recruiting
- Conditions
- ovel desensitization protocol based on platelet, Anti-HLA antibody ,Kidney transplant, Desensitization.Kidney transplantZ94.0
- Registration Number
- IRCT20221101056360N1
- Lead Sponsor
- Bagheiat-allah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Being over 18 years old and under 70 years old
No current infectious or neoplastic disease
Having favorable results on cardiac examination in the last three months
Patients with CPRA greater than 95%
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CPRA: The CPRA estimates the percentage of donors with whom a particular recipient would be incompatible . If CPRA is more than 95%, our patient needs desensitization. Timepoint: Before desensitization, two months after desensitization. Method of measurement: Lab test : Calculated panel reactive antibody.
- Secondary Outcome Measures
Name Time Method The amount of antibodies against HLAI and HLAII subunits as mean fluorescent intensity (MFI) in the LUMINEX method. Timepoint: Before desensitization, two months after desensitization. Method of measurement: Mean Fluorescence Intensity Donor-Specific Anti-HLA Antibodies on LUMINEX platform (lab test).